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Abstract
Background: Cardiovascular Magnetic Resonance (CMR) with adenosine stress is a valuable diagnostic tool in
coronary artery disease (CAD). However, despite the development of MR conditional pacemakers CMR is not yet
established in clinical routine for pacemaker patients with known or suspected CAD. A possible reason is that
adenosine stress perfusion for ischemia detection in CMR has not been studied in patients with cardiac conduction
disease requiring pacemaker therapy. Other than under resting conditions it is unclear whether MR safe pacing
modes (paused pacing or asynchronous mode) can be applied safely because the effect of adenosine on heart rate
is not precisely known in this entity of patients. We investigate for the first time feasibility and safety of adenosine
stress CMR in pacemaker patients in clinical routine and evaluate a pacing protocol that considers heart rate
changes under adenosine.
Methods: We retrospectively analyzed CMR scans of 24 consecutive patients with MR conditional pacemakers
(mean age 72.1 ± 11.0 years) who underwent CMR in clinical routine for the evaluation of known or suspected
CAD. MR protocol included cine imaging, adenosine stress perfusion and late gadolinium enhancement.
Results: Pacemaker indications were sinus node dysfunction (n = 18) and second or third degree AV block (n = 6).
Under a pacing protocol intended to avoid competitive pacing on the one hand and bradycardia due to AV block
on the other no arrhythmia occurred. Pacemaker stimulation was paused to prevent competitive pacing in sinus
node dysfunction with resting heart rate >45 bpm. Sympatho-excitatory effect of adenosine led to a significant
acceleration of heart rate by 12.3 ± 8.3 bpm (p < 0.001), no bradycardia occurred. On the contrary in AV block heart
rate remained constant; asynchronous pacing above resting heart rate did not interfere with intrinsic rhythm.
Conclusion: Adenosine stress CMR appears to be feasible and safe in patients with MR conditional pacemakers.
Heart rate response to adenosine has to be considered for the choice of pacing modes during CMR.
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Background
Cardiovascular magnetic resonance (CMR) as a non-
invasive imaging modality is firmly established in the
clinical workup for patients with known or suspected
CAD. It has become the gold standard for chamber
quantification and detection of left ventricular wall mo-
tion impairment in ischemic cardiomyopathy [1–3]. Post
myocardial infarction (MI) complications such as nega-
tive remodeling, formation of aneurysms and intraven-
tricular thrombi, pericardial effusion and ischemic mitral
valve regurgitation can be detected precisely even in
obese patients less suitable for echocardiographic assess-
ment [4]. It has become the most important technique
for tissue characterization such as scar detection in MI
[5], and a stand alone imaging modality in differential
diagnosis in ischemic versus other cardiomyopathies
such as myocarditis [1]. Adenosine stress perfusion im-
aging plays a major role in the assessment of unknown
coronary status [3, 6]. It has a class Ia level A recom-
mendation in case of intermediate pre test probability of
CAD in latest guidelines [3]. Hemodynamic relevance of
stenoses in known CAD can be evaluated reliably [7].
In patients with sinus node dysfunction (SND) and
AV-block underlying or concomitant CAD is common
[8, 9]. In both disorders adenosine administration is only
permitted with a permanent PM in situ due to possible
bradycardia [10]. A high number of patients with SND
or AV-block undergo PM implantation [11]; taken to-
gether both disorders constitute the majority of pace-
maker indications worldwide [12].
In the past presence of a pacemaker was regarded as a
contraindication for MR scanning [13, 14]. Nevertheless
a number of studies have been conducted in these patients
showing no relevant complications and sufficient overall
image quality [15–19]. Recent development of MR condi-
tional PM has opened this technology for patients with
PM in clinical routine [20]. While safety of CMR without
stress agents in patients with MR conditional PM has been
shown in a number of studies [21–23], apart from single
cases [17, 24] there is no data available on adenosine stress
perfusion imaging in patients with PM neither conven-
tional nor MR conditional.
In MR conditional PM only deactivation (ODO-mode)
or asynchronous pacing (DOO, AOO, VOO) [25] are
available to avoid inhibition by electromagnetic interfer-
ence or tracking of electromagnetic signals. In SND and
AV-block selecting an adequate pacing mode for routine
adenosine stress CMR can be challenging because the ef-
fect of adenosine on heart rate (HR) is not precisely
known in this entity of patients. On the one hand asyn-
chronous mode (i.e. pacing at a fixed rate above baseline
HR) could result in competitive pacing: HR can acceler-
ate under adenosine [26] reaching the fixed pacing rate
without inhibiting PM activity because sensing and
inhibition is deactivated in this mode. PM stimulation
could then fall in the vulnerable period of the cardiac
cycle and trigger arrhythmia [27]. On the other hand de-
activation of pacing in patients with normal HR under
resting conditions could result in bradycardia or asystole
under adenosine [10].
In conclusion the high value of adenosine stress CMR
in known or suspected CAD is well established but it is
still unknown whether the method is safe and feasible in
PM patients with SND or AV block who are pro-
grammed to the restricted pacing modes required by
MRI conditional devices during performance of CMR.
We investigate for the first time feasibility and safety of
CMR in clinical routine in PM patients.
Methods
We retrospectively analyzed MR scans of 24 consecutive
patients with MR conditional PM who underwent routine
adenosine stress CMR for the evaluation of known or sus-
pected CAD including cine imaging, adenosine stress per-
fusion and late gadolinium enhancement after informed
consent was obtained from March 2014 to April 2015.
The study complied with the Declaration of Helsinki and
was approved by the local Institutional Review Board
(University of Witten/Herdecke, Medical Faculty).
Pacemaker programming
CMR was performed more than six weeks after PM im-
plantation in all individuals according to ESC guidelines
[13]. Prior to CMR imaging battery status of the device,
lead impedance, pacing capture thresholds and sensing
amplitudes were measured.
Devices were set to MR safe mode according to manu-
facturer’s instructions immediately prior to the scan and
reprogrammed immediately thereafter. Programming was
performed according to a predefined protocol: To avoid
interference of intrinsic rhythm with PM-stimulation in
patients with SND and resting heart rate HR > 45 bpm no
pacing (ODO)-mode was engaged during the scan - also
when atrial fibrillation (AF) was present at the time of the
scan. In individuals with SND and HR ≤ 45 bpm the pace-
maker was set to asynchronous atrial stimulation (AOO,
60 bpm). All patients with intermittent or permanent sec-
ond or third degree AV block were continuously paced in
asynchronous mode irrespective of their actual rhythm
and HR to avoid possible asystole or bradycardia due to
worsening AV conduction induced by adenosine. Pacing
rate was set 10 bpm above spontaneous heart rate with a
minimum of 60 bpm. VOO mode at 60 bpm was chosen
in AV block with sinus rate > 45 bpm to avoid competitive
atrial stimulation, DOO mode at 60 bpm in AV block with
sinus bradycardia ≤ 45 bpm. Patients in AF at the time of
the scan were paced VOO at 60 bpm if resting heart rate
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was ≤ 45 bpm. Table 1 shows the pacing protocol used to
select pacing modes for specific clinical constellations.
Safety precautions
Patients were monitored during the scan with continuous
electrocardiographic and visual supervision by a cardiolo-
gist present in the scanner room. Voice contact was main-
tained with the patient at all times of the scan. Advanced
cardiac life support protocol was in effect. In the scanner
the patient was placed on a carry sheet; medical staff was
trained for rapid removal of the patient from the scanner
room in the event of cardiopulmonary compromise.
Thus immediate treatment of severe arrhythmia and
reactivation of PM stimulation within seconds in non-
paced patients was guaranteed. Atropine, adrenaline
and theophylline injections were prepared ready for use
in case of bradycardia. Two separate cubital venous
cannulas were used for adenosine and gadolinium con-
trast agent respectively.
Cardiovascular magnetic resonance
CMR was performed with a 1.5 T wide bore system
(ESPREE – Siemens Healthcare, Erlangen, Germany)
using a 4-channel body array and an 8-channel spine
coil. Maximum gradient field was 33 mT/m (Z-Engine)
with a slew rate of 100 T/m/s. Maximum specific ab-
sorption rates were limited to 2.0 W/kg.
Our standard protocol meets the Society of Cardiovas-
cular Magnetic Resonance (SCMR) standards for CMR
[1]. Cine steady-state free precession (SSFP) gradient-
echo images were obtained in 10 to 12 short axis slices
depending on the size of the ventricles and in 3 long axis
planes corresponding to two, three and four chamber
views. For stress perfusion-imaging adenosine was ad-
ministered as 3-min infusion of 140ug/kg body weight/
min. First-pass perfusion imaging was carried out with
intravenous bolus administration of gadolinium (0.2
mmol/kg body weight) in a fast low angle shot (FLASH)
sequence (3 to 4 slices). Late Gadolinium Enhancement
(LGE) images were acquired fifteen minutes after injec-
tion of gadolinium as phase-sensitive inversion-recovery
(PSIR) in short (10 to 12 slices) and long axis (3 planes)
views. Table 2 shows details of the MR protocol.
Results
General characteristics
Twenty-four CMR examinations were analyzed. Patients
had a mean age of 72.1 ± 11.0 years. 11 (45.8 %) had
known CAD, 7 (29.1 %) previous MI. All other patients
had intermediate pretest probability of CAD [28]. Echo-
cardiography had shown preserved systolic left ventricular
(LV) function in all subjects. Pacemaker indications were
sinus node dysfunction (SND) (n = 18; 75 %) and second or
third degree AV-block (n = 6; 25 %). No patient was PM
dependent (HR <30 bpm). Impulse generator/lead models
were Advisa (n = 5; 20.8 %) and Ensura (n = 18; 75 %)
MRI SureScan/CapSureFix 5076 Novus (atrial), CapSure-
Sense 4074 (ventricular) (Medtronic Inc., Minneapolis,
MA, USA); Entovis DR-T/Safio S 53 (atrial), Safio S60
(ventricular) (Biotronik SE & Co. KG, Berlin, Germany),
n = 1, 4.2 %. For detailed baseline characteristics see
Table 3.
Effect and safety of adenosine administration for stress
perfusion
There were no adenosine induced adverse events.
In 17 patients with SND and normal AV-conduction
(n = 14) or normofrequent AF (n = 3) at the time of the
scan the pacemaker stimulation was deactivated (ODO).
Adenosine administration accelerated mean HR by 12.3 ±
8.3 bpm (p = 0.001). AV-conduction was not significantly
influenced by adenosine; no higher degree AV block oc-
curred. When sinus rate was <45 bpm (n = 1) AOO
pacing at 60 bpm led to permanent capture, no acceler-
ation of HR under adenosine was noticed.
In patients with second or third degree AV block and
sinus rate >45 bpm (n = 5) that were paced asynchron-
ously no arrhythmia was detected; permanent ventricu-
lar capture was seen on ECG monitoring during the
scan. One patient with intermittent second degree AV
block but with normal AV conduction at the time of
CMR was paced 10 bpm above spontaneous HR. When
sinus rate was <45 bpm (n = 1) D00 pacing at 60 bpm
was engaged and did not lead to competitive atrial
stimulation. No competitive ventricular stimulation was
observed. Adenosine did not induce tachycardia.
Figure 1 summarizes individual HR response under
adenosine in non-paced patients with SND.
Device integrity
Device integrity was not compromised by the CMR scan.
Lead impedance was unchanged pre and post CMR for
atrial and ventricular leads. Pacing capture thresholds
were equally unaffected. Sensing amplitudes remained
unchanged as well as battery voltage. Table 4 summa-
rizes device parameters pre and post CMR.
Table 1 Protocol for the selection of pacing modes
Sinus rate > 45 bpm Sinus rate ≤ 45 bpm
Sinus node dysfunction
without AV-block > I°
ODO AOO at 60 bpm
AV-block > I°
(present or history of)
VOO at 10 bpm > IHR DOO at 60 bpm
Atrial fibrillation at
time of scan
VOO at 60 bpm
when HR <45 bpm
bpm, Beats per minute, AV Atrioventricular, IHR Intrinsic heart rate
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Diagnostic value of cine sequences, late gadolinium
enhancement and adenosine stress perfusion
CMR showed preserved ejection fraction in all patients.
Image quality was sufficient to calculate ejection fraction
in long axis views despite moderate PM artifacts in all
patients and corresponded to echocardiographic findings.
Regional wall motion impairment was seen in 6 (25.0 %),
LV hypertrophy in 7 (29.2 %) patients. Minor valve dys-
function was found in 3 (12.5 %) patients, aortic
aneurysm > 45 mm in 2 (8.3 %) patients. LGE with suben-
docardial or transmural distribution pattern corresponding
to post MI scarring was present in 7 (29.2 %) patients and
was not obscured by PM artifacts caused by generator or
leads. Postinflammatory myocardial scarring was seen in
one patient. Adenosine induced perfusion deficit was visible
in two patients. One patient consecutively underwent per-
cutaneous coronary intervention with stent implantation in
the right coronary artery; the second patient was scheduled
for bypass surgery.
See Fig. 2 for examples of cine sequences, first pass per-
fusion and LGE in a patient without previously known
CAD. Stress perfusion compared to resting perfusion
shows a perfusion deficit in viable myocardium corre-
sponding to consecutive invasive coronary angiogram.
Discussion
The present study shows no complications of adenosine
stress CMR related to the presence of a PM or the
underlying cardiac conduction disorder. The device
remained intact; no arrhythmia was induced by adeno-
sine in this highly selected entity of patients.
Table 2 Details of the CMR protocol
Objective Sequence Plane TR/TE (ms) Slice thickness
(mm)





1000/44 8 27/35 125×256/142×256 290/360 160 1
Cine imaging True FISP Long and short
axes
66/1.6 8 LA: 3SA: 10/12 166×256 300/370 79 1
First pass perfusion GRE Short axes 176/1.2 8 3/4 96×128 260/300 15 1
Late Gadolinium
Enhancement
PSIR Long and short
axes
1024/3.5 8 LA: 3SA: 10/12 144×256 270 25 0
HASTE Half fourier acquisition single shot turbo spin echo, LA Long axis, SA Short axis, TR Repetition time, TE Echo time, FOV Field of view, PAT Parallel acquisition
technique, True FISP, True fast imaging with steady state precession, GRE Gradient echo, PSIR Phase-sensitive inversion recovery
Table 3 Baseline characteristics
Total patients 24




Higher degree AV Block 6 25.0
Sinus node dysfunction 18 75.0
Coronary artery disease 11 45.8
Paroxysmal atrial fibrillation 10 41.7
Hypertension 19 79.2
Impaired renal function 4 16.7
Previous Stroke 7 29.2
Pacemaker
Ensura DR MRI Sure Scan EN1DR01 18 75.0
Advisa DR MRI Sure Scan A3DR01 5 20.8
Entovis DR-T 1 4.2
Implantation site left pectorally 16 66.7
Pacemaker dependent 0






Fig. 1 Adenosine effect on heart rate in sinus node dysfunction.
Individual changes of heart rate in 17 non-paced patients with SND
in SR or momentary AF under adenosine administration, solid lines:
sinus rhythm, dotted lines: AF, *paired t-test. SND, sinus node
dysfunction; SR, sinus rhythm, AF, atrial fibrillation
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Safety of adenosine administration
Apart from influence of the MR field on device function,
the most important safety issue in adenosine stress CMR
is the MR conditional pacing mode itself. Only asyn-
chronous pacing without sensing or deactivation can be
programmed in this mode to avoid tracking of electro-
magnetic impulses and inhibition by electromagnetic
interference [13]. Thus two possible risks should be ad-
dressed: proarryhythmia due to competitive pacing in
the vulnerable period of the cardiac cycle on the one
hand, bradycardia or asystole due to missing backup
pacing on the other. Some investigators estimate the risk
of asynchronous pacing to be low [29]. However, for
routine adenosine stress CMR in CAD sequences for
localization, cine imaging, first pass perfusion and LGE
are necessary - with additional sequences (tissue
characterization, flow analysis) even longer periods in
MR conditional mode may be required. Paused or asyn-
chronous PM stimulation may be of relevance under
these conditions.
This issue is complicated by the effect of adenosine on
HR during stress perfusion: The negative dromotropic
effect of the substance on the cardiac conduction system
may result in bradycardia or asystole in patients with
paused PM stimulation [30, 31]. On the other hand dir-
ect receptor-specific stimulation of sympathetic affer-
ences can result in sinus tachycardia that can interfere
with fixed pacing rates in asynchronously paced individ-
uals [32, 33].
The present data suggests that in SND with normal
resting HR and preserved AV conduction paused PM
stimulation (ODO mode) is suitable for adenosine stress
perfusion. Apart from one patient with constant HR we
found a significant increase in HR i.e. no negative dro-
motropic effect of adenosine in SND with an adenosine
dosage of 140ug/kg/min limited to three minutes. Thus
the direct sympatho-excitatory effect of adenosine over-
rides cardiac inhibition comparable to patients without
SND. In AF we also found predominance of the
sympatho-excitatory reflex with positive chronotropy.
Choosing asynchronous pacing would have been prob-
lematic in SND because adenosine accelerated HR by
up to 29 bpm. Pacing far above baseline HR for a lon-
ger time could cause discomfort or even circulatory
compromise in PM patients adapted to relative brady-
cardia [34].
We propose asynchronous pacing in AV block because
the risk of asystole under adenosine is high [35], persist-
ent AV-block after cessation of adenosine infusion has
been described [36]. HR remained constant because AV
conduction was impaired and increase in sinus rate due
to sympathetic stimulation did not translate into tachy-
cardia making competitive pacing unlikely. However this
may depend on the severity of the AV conduction dis-
order. Functional conduction delay may be overcome;
structurally damaged AV conduction in higher degree
AV block is unlikely to recover under sympathetic
stimulation. In patients with intermittent AV block but
normal AV conduction pre CMR we chose pacing only
10 bpm above resting HR, however this may not always
be adequate. AV conduction could stay intact even under
adenosine allowing acceleration of HR beyond the fixed
pacing rate. The optimum pacing rate in this group of
patients has to be evaluated in larger studies; even in-
activation of the pacemaker could be adequate in AV
block with normal AV conduction at the time of MR
provided that immediate cessation of adenosine infusion
and fast reactivation of pacing are guaranteed.
In the present study no proarrhythmia was observed
under individually adapted pacing modes; nevertheless
arrhythmia is the main safety issue. Calculating the risk
of arrhythmia one has to take into account that severe
brady- or tachycardia has been described almost exclu-
sively for bolus administration of adenosine; malignant
reentrant tachycardia due to accessory pathways is pre-
dominant [37]. In continuous slow application of adeno-
sine persistent and life threatening bradycardia is
unlikely to occur due to the short half-life of only several
seconds [35]; on the contrary severe arrhythmia induced
by competitive pacing may persist [27, 38]. Nevertheless
caution in this warranted. Pharmacologic therapy of
arrhythmia and reactivation of paused PM stimulation
must be available immediately. For ischemia detection
the possible risk of arrhythmia in adenosine stress CMR
under asynchronous or deactivated pacing should be
weighed against possible risks and diagnostic limitations
of other non-invasive tests like stress echo and scintig-
raphy or invasive coronary angiography. Thus the value
of CMR in the workup of CAD in PM patients has to be
compared to other diagnostic strategies, namely when
the high supervisory expense in this setting is consid-
ered. We encourage prospective randomized studies to
clarify which imaging strategy is the best choice for PM
patients in term of safety and clinical value.
Table 4 Comparison of device parameters before and after
CMR
Before MR After MR P*
P-wave amplitude (mV) 2.87 ± 1.86 3.10 ± 1.70 0.32
R-wave amplitude (mV) 12.27 ± 5.32 12.05 ± 5.44 0.59
Atrial lead impedance (Ohm) 469 ± 61 468 ± 65 0.65
Ventricular lead impedance (Ohm) 601 ± 120 603 ± 118 0.57
Atrial PCT (V@0.4 ms) 0.66 ± 0.25 0.66 ± 0.20 1.0
Ventricular PCT (V@0.4 ms) 0.63 ± 0.26 0.55 ± 0.28 0.1
Battery voltage (V) 2.97 ± 0.42 2.97 ± 0.42 n.a.
CMR Cardiovascular magnetic resonance, PCT Pacing capture threshold,
*Wilcoxon signed rank test
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Diagnostic value
While several publications have noted rather minimal
artifact and the ability to produce diagnostic scans, others
have noted compromised CMR images because of artifact
[39]. In this study PM artifacts caused no clinically relevant
compromise of image quality. In AV block the principle of
ischemia detection by adenosine should be unaffected by









Fig. 2 Adenosine stress CMR and subsequent coronary angiogram in a patient with AV block, suspected coronary artery disease and pathologic
CMR. Cine imaging (a, b) shows small apical aneurysm (a, arrow); myocardium can be delineated (b, arrow) despite PM lead artifact (small
arrows). Stress perfusion shows perfusion deficit in LAD and RCA territory (c, small arrows) not visible in resting perfusion (d); PM lead artifact is
visible (asterixes). LGE (e/f) shows myocardial scarring apically (arrow) and viable myocardium in the ischemic area seen on stress perfusion (c).
No major compromise of image quality by PM artifacts is present. Coronary angiogram corresponds to CMR findings with chronic total occlusion
of RCA (g, arrow) and LAD (h, arrow). CMR, Cardiovascular Magnetic Resonance; AV, atrioventricular; PM, pacemaker; LAD, left anterior descendent
coronary artery; RCA, right coronary artery; LGE, Late Gadolinium Enhancement
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induced by vasodilatation via cardiac A1 receptors and not
by positive chronotropy like in dobutamine stress [40].
However increase in heart rate as a marker of adeno-
sine response is unavailable in those patients; side ef-
fects of adenosine like respiratory symptoms may be no
reliable indicator for a systemic effect of adenosine.
The splenic switch-off sign as described by Mainsty
et al. [41] may be a helpful indicator to detect insuffi-
cient adenosine stress requiring higher adenosine dos-
age. Adenosine stress perfusion for ischemia detection
has been studied in single photon emission computed
tomography imaging and scintigraphy [42] but not in
CMR. As proof of concept in this study severe CAD
could be detected in one patient with AV block and
perfusion deficit under adenosine. Larger prospective
studies have to confirm diagnostic value of stress perfu-
sion MR in this subgroup of patients.
Device integrity
The present data on lead integrity are in line with pre-
vious studies on MR conditional PM [22, 23] showing
no clinically significant alterations of lead impedance,
pacing capture threshold and sensing amplitude. Sig-
nificantly reduced battery voltage (BV) immediately
after MR has been described for MR conditional
models [21]. Thus in theory repeated MR scans could
result in reduced longevity of the systems. We found
unchanged battery status post CMR in all patients.
Thus our results support the finding of Claas et al. [43]
showing no decrease of BV above the accuracy of meas-
urement post MR. Clinically relevant reduction of BV
by routine adenosine stress CMR in patients with MR
conditional PM is unlikely taking also into account that
a decrease of 0.05 V does not seem to reduce longevity
of the PM to a clinically relevant extent [44].
Limitations
This study is limited by the small sample size and the lack
of a control group. Adverse effects may only appear in a lar-
ger cohort of patients. No intermediate or long-term follow
up data was provided. Moreover the diagnostic value of
CMR was not evaluated invasively in patients without per-
fusion deficit.
Conclusion
Our data suggest adenosine stress CMR in patients with
MR conditional PM to be feasible and safe for the
workup of CAD. We propose individualized pacing
modes to reduce the risk of proarrhythmia that have to
be further evaluated. Adenosine induced sympathetic
stimulation overrides inhibitory effects on the conduc-
tion system leading to positive chronotropy only in pa-
tients with intact AV conduction but not in higher
degree AV block. We encourage further research to
determine the diagnostic value of adenosine stress CMR
in PM patients and to establish guidelines on pacemaker
programming for adenosine stress in clinical routine.
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